Waters Corporation announced on May 28, 2025, the launch of its BioResolve™ Protein A Affinity Columns with MaxPeak™ Premier Technology, designed to provide precise antibody titer measurements. This marks Waters' first set of affinity chromatography columns brought to market, addressing unmet needs in large molecule separations.
These new columns enable earlier access to results in upstream bioprocessing and faster method optimization in downstream development for biologics. They offer a new level of agility in the discovery, optimization, and manufacturing of antibody-based drug products.
The BioResolve Protein A Affinity Columns are engineered to provide up to 7x improvements in sensitivity compared to the market leader. Their novel, non-porous 3.5 μm particles allow for accurate quantitation of antibody titers at lower concentrations and with less sample, accelerating the development of life-saving therapies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.